
|Videos|November 1, 2017
Dr. Armstrong Discusses Hereditary Prostate Cancer
Author(s)Andrew J. Armstrong, MD
Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.
Advertisement
Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.
One of the most important findings of the past year was the identification of a form of hereditary prostate cancer, Armstrong says.
These mutations are called homologous repair enzymes, which create a very aggressive form of prostate cancer that effects 10% to 15% of men with metastatic prostate cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































